 Home > Medical News > Medicines Company News > Innovent BioORIENT-31 studies that sindilizumab combined with chemotherapy in EGFR mutant non-squamous non-small cell lung cancer obtained a significant prolongation of PFS

Innovent BioORIENT-31 studies that sindilizumab combined with chemotherapy in EGFR mutant non-squamous non-small cell lung cancer obtained a significant prolongation of PFS

 Last Update: 2022-09-21
 Source: Internet
 Author: User

Tags

1 4 fitting

state slim phase 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cinda Biopharma Group (HKEx: 01801), a biopharmaceutical company dedicated to the development, production and marketing of innovative drugs in the field of major diseases such as oncology, self-immunity, metabolism, ophthalmology and other major diseases, announced the combination or non-combination ® of Dabshu ® (Sindili Monoclonal Antibody Injection) in the form of an oral report (Abstract No.

The results of the second interim analysis showed that in the population of intent therapy (ITT), based on the Independent Imaging Evaluation Board (IRRC) assessment, the mPFS (95% CI) of Daboshu ® (sindili maclizumab injection) + Dayoutong ® (bevacizumab analogue) combined with chemotherapy group (trial group A), Daboshu ® (sindili mabumab injection) combined with chemotherapy group (trial group B) and chemotherapy group (control group C) were 7.

Professor Lu Shun, the main investigator of the ORIENT-31 study, from the Department of Oncology of Shanghai Chest Hospital, said: "EGFR-TKI targeted therapy is the preferred treatment plan for patients with EGFR-sensitive mutation NSCLC, but after using TKI drugs, almost all patients will eventually appear resistant and lead to disease progression, and the efficacy of platinum-containing chemotherapy after drug resistance is not ideal, so the problem of drug resistance and the choice of treatment after drug resistance have become the main concerns of clinicians

Dr.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.